What is a multi-cancer early detection (MCED) test?

An MCED test looks for a shared signal of cancer across many cancer types from a single blood draw. As tumours grow, they shed fragments of cell-free DNA (cfDNA) into the bloodstream. Cancer cells carry distinctive DNA methylation patterns — chemical marks on the DNA that differ from healthy tissue. A pan-cancer methylation test sequences these patterns and uses them to flag whether a cancer signal is present, and often to predict the likely tissue of origin. Unlike a single-organ test (such as a mammogram or colonoscopy), one MCED blood draw screens for a broad range of cancers at once, including several that have no standard screening test today.

How early can it detect cancer?

The honest answer: earlier than symptoms, sometimes earlier than imaging — but not as a guarantee, and not for every cancer. Methylation changes are among the earliest molecular events in cancer, which is why these assays can flag a signal before a tumour is large enough to see on a scan or cause symptoms. Marketing often quotes a 6–12-month lead over imaging; in published series, detection ahead of clinical diagnosis is real but variable by cancer type and stage. Sensitivity is higher for later-stage and for biologically aggressive cancers, and lower for very early, slow-growing or low-shedding tumours. We present this as a probabilistic early-warning tool, not a crystal ball.

How accurate is it — what about false results?

Pan-cancer methylation MCED tests are designed for high specificity (low false-positive rate, typically around 99% in validation cohorts), which keeps unnecessary follow-up workups rare. The trade-off is sensitivity: overall detection across all stages sits well below 100% and is lowest at stage I, so a negative result does not rule cancer out. A positive result is not a diagnosis — it triggers a diagnostic workup (imaging, and biopsy if a lesion is found) to confirm and locate the cancer. Predicted tissue-of-origin accuracy is good but imperfect. Large prospective trials (including the UK NHS-Galleri study) are still maturing the real-world performance picture, and we say so plainly.

Does it replace mammograms, colonoscopy or low-dose CT?

No. An MCED test complements guideline-based screening; it does not replace it. Established single-organ screening — mammography, colonoscopy, cervical screening, low-dose chest CT for eligible smokers — remains the standard of care and detects cancers an MCED test can miss. The value of a pan-cancer test is breadth: it can flag cancers with no routine screening pathway (pancreatic, ovarian, liver, oesophageal and others). The right use is additive — keep your standard screening calendar and add MCED as a wider net, not as a substitute.

Who is it most useful for?

It is most informative for adults at elevated baseline cancer risk: those over roughly 50, people with a significant personal or family cancer history, long-term smokers, and individuals with known hereditary risk (for example a confirmed TP53 or BRCA variant — see our TP53 testing page). For a healthy 30-year-old with no risk factors, the pre-test probability of cancer is low, so even a high-specificity test yields a less favourable balance of benefit to incidental workup. We discuss your individual risk profile before recommending the test.

How much does pan-cancer methylation testing cost in China?

All-in international-patient pricing for a pan-cancer methylation MCED blood test runs roughly $900–$2,600 depending on the assay, the panel breadth and whether tissue-of-origin prediction is included — materially below the $950+ list price of comparable tests in the US before workup costs. The price covers the blood draw, laboratory analysis and a bilingual report. Any positive-signal diagnostic workup (imaging, endoscopy, biopsy) is quoted separately and coordinated within the program.

Can foreigners get this test in China, and how?

Yes. International patients access pan-cancer methylation testing through the health-management and oncology departments of Class A hospitals and licensed reference laboratories, with bilingual coordination. Panda Touring Care arranges the blood draw (which can often be combined with a longevity phenotyping visit), the laboratory analysis, a clinician-reviewed bilingual report, and — if a signal is detected — the confirmatory diagnostic pathway at the same Class A hospital.

Precision screening · MCED

One blood draw,
a wider cancer net.

Pan-cancer methylation testing reads tumour-specific DNA marks in cell-free DNA to flag a cancer signal — often before imaging or symptoms, and across cancers with no routine screening. Delivered at China’s Class A hospitals from $900, graded honestly: a powerful adjunct, never a replacement for standard screening.

Get a screening assessment Back to longevity hub

1 draw

Many cancers

Single blood test screens broadly

Assay design

cfDNA

Methylation signal

Tumour-specific DNA marks

Molecular oncology

~99%

Specificity

Low false-positive rate in validation

MCED literature

$900–2.6k

All-in cost

Below US list pricing

Partner quotes 2026

Add-on

Not a replacement

Complements standard screening

Editorial standard

Class A

All partner labs

Licensed reference laboratories

NHC / NMPA

The idea

Catch the signal
before the scan can.

Most cancer screening checks one organ at a time, and several deadly cancers — pancreatic, ovarian, liver — have no routine screening test at all. A multi-cancer early detection (MCED) test takes a different angle: it reads the molecular fingerprint cancer leaves in the blood, from a single draw.

The fingerprint is DNA methylation. Tumour cells shed fragments of cell-free DNA carrying methylation marks that look nothing like healthy tissue. Because those marks appear early in cancer’s development, a pan-cancer methylation assay can flag a signal before a tumour is visible on imaging — and predict where in the body it likely came from.

We frame this carefully. The science is genuine and the breadth is real, but a positive result is a prompt for workup, not a diagnosis, and a negative result is not a clearance. MCED is an adjunct that widens the net alongside your colonoscopy, mammography and other standard screening — part of the precision-screening layer of longevity medicine.

How it works

From cfDNA to a clear next step.

Step 1

Tumour sheds cfDNA

Growing tumours release fragments of cell-free DNA into the bloodstream alongside the DNA shed by healthy cells. A standard blood draw captures the mix.

Step 2

Methylation is read

The assay sequences the DNA methylation pattern — chemical marks that differ sharply between cancerous and healthy tissue — across thousands of genomic regions.

Step 3

Signal is classified

Machine-learning models trained on large cohorts judge whether a cancer signal is present and, in most assays, predict the likely tissue of origin to guide follow-up.

Step 4

Workup confirms

A positive signal is never a diagnosis. It directs targeted imaging and, if a lesion is found, biopsy — to confirm, locate and stage any cancer before treatment.

How we position it

Four things we tell every patient.

Value

Breadth, not a single organ

Its real advantage is catching cancers with no routine screening pathway — pancreatic, ovarian, liver, oesophageal — from the same draw that an annual checkup already involves.

Quality

High specificity by design

Tuned to keep false positives rare (~99% specificity), so a positive result is meaningful enough to act on, and unnecessary workups stay uncommon.

Honesty

A negative is not a clearance

Sensitivity is incomplete, especially at stage I. We will not tell you a negative result means you are cancer-free — only that no signal was detected this cycle.

Honesty

Evidence still maturing

Large prospective outcome trials are ongoing. We present MCED as a promising adjunct, grade it as emerging, and pair it with — never instead of — guideline screening.

Multi-cancer early detection is an emerging technology with maturing prospective evidence. We present it as a high-specificity adjunct to guideline-based screening, not a substitute, and we will tell you when standard screening alone is the better-evidenced choice for your risk profile.

The pathway

From blood draw
to a confirmed answer.

Step 1

Risk review

We review your age, personal and family cancer history and risk factors to confirm an MCED test is informative for you — or recommend standard screening alone if it is not.

Step 2

Blood draw

A single blood sample is collected at a Class A hospital, often combined with a longevity phenotyping visit or executive physical to save a trip.

Step 3

Laboratory analysis

The licensed reference lab sequences cfDNA methylation and runs the classifier. Turnaround is typically 10–15 business days.

Step 4

Clinician-reviewed report

An oncologist reviews the result and you receive a bilingual report — including predicted tissue of origin where a signal is found, and clear next-step guidance.

Step 5

Confirmatory pathway

If a signal is detected, we coordinate targeted imaging and biopsy at the same Class A hospital, with bilingual records and a treatment plan if cancer is confirmed.

FAQ

Multi-cancer detection, answered.

What is a multi-cancer early detection (MCED) test?: An MCED test looks for a shared signal of cancer across many cancer types from a single blood draw. As tumours grow, they shed fragments of cell-free DNA (cfDNA) into the bloodstream. Cancer cells carry distinctive DNA methylation patterns — chemical marks on the DNA that differ from healthy tissue. A pan-cancer methylation test sequences these patterns and uses them to flag whether a cancer signal is present, and often to predict the likely tissue of origin. Unlike a single-organ test (such as a mammogram or colonoscopy), one MCED blood draw screens for a broad range of cancers at once, including several that have no standard screening test today.
How early can it detect cancer?: The honest answer: earlier than symptoms, sometimes earlier than imaging — but not as a guarantee, and not for every cancer. Methylation changes are among the earliest molecular events in cancer, which is why these assays can flag a signal before a tumour is large enough to see on a scan or cause symptoms. Marketing often quotes a 6–12-month lead over imaging; in published series, detection ahead of clinical diagnosis is real but variable by cancer type and stage. Sensitivity is higher for later-stage and for biologically aggressive cancers, and lower for very early, slow-growing or low-shedding tumours. We present this as a probabilistic early-warning tool, not a crystal ball.
How accurate is it — what about false results?: Pan-cancer methylation MCED tests are designed for high specificity (low false-positive rate, typically around 99% in validation cohorts), which keeps unnecessary follow-up workups rare. The trade-off is sensitivity: overall detection across all stages sits well below 100% and is lowest at stage I, so a negative result does not rule cancer out. A positive result is not a diagnosis — it triggers a diagnostic workup (imaging, and biopsy if a lesion is found) to confirm and locate the cancer. Predicted tissue-of-origin accuracy is good but imperfect. Large prospective trials (including the UK NHS-Galleri study) are still maturing the real-world performance picture, and we say so plainly.
Does it replace mammograms, colonoscopy or low-dose CT?: No. An MCED test complements guideline-based screening; it does not replace it. Established single-organ screening — mammography, colonoscopy, cervical screening, low-dose chest CT for eligible smokers — remains the standard of care and detects cancers an MCED test can miss. The value of a pan-cancer test is breadth: it can flag cancers with no routine screening pathway (pancreatic, ovarian, liver, oesophageal and others). The right use is additive — keep your standard screening calendar and add MCED as a wider net, not as a substitute.
Who is it most useful for?: It is most informative for adults at elevated baseline cancer risk: those over roughly 50, people with a significant personal or family cancer history, long-term smokers, and individuals with known hereditary risk (for example a confirmed TP53 or BRCA variant — see our TP53 testing page). For a healthy 30-year-old with no risk factors, the pre-test probability of cancer is low, so even a high-specificity test yields a less favourable balance of benefit to incidental workup. We discuss your individual risk profile before recommending the test.
How much does pan-cancer methylation testing cost in China?: All-in international-patient pricing for a pan-cancer methylation MCED blood test runs roughly $900–$2,600 depending on the assay, the panel breadth and whether tissue-of-origin prediction is included — materially below the $950+ list price of comparable tests in the US before workup costs. The price covers the blood draw, laboratory analysis and a bilingual report. Any positive-signal diagnostic workup (imaging, endoscopy, biopsy) is quoted separately and coordinated within the program.
Can foreigners get this test in China, and how?: Yes. International patients access pan-cancer methylation testing through the health-management and oncology departments of Class A hospitals and licensed reference laboratories, with bilingual coordination. Panda Touring Care arranges the blood draw (which can often be combined with a longevity phenotyping visit), the laboratory analysis, a clinician-reviewed bilingual report, and — if a signal is detected — the confirmatory diagnostic pathway at the same Class A hospital.

Continue exploring

TP53 Genetic Testing

Read your inherited cancer-defence baseline — the guardian-of-the-genome gene.

Read on TP53

Cellular Function Testing

A 113-marker scan of metabolic and cellular function behind fatigue and decline.

Read on cell function

WT1 Cancer Vaccine

Where therapeutic cancer vaccines fit — and where they don't.

Read on WT1

Cancer Treatment in China

If a signal is confirmed — the full oncology pathway at Class A hospitals.

See oncology

Health Checkup in China

The comprehensive executive physical this test pairs with.

See checkups

Longevity Medicine Hub

The full screening-and-intervention overview.

Back to hub

Is MCED right
for your risk profile?

Tell us your age, family cancer history and current screening calendar. We will tell you honestly whether a pan-cancer methylation test adds value for you — and arrange it alongside your standard screening if it does.

Book a screening assessment Back to longevity hub

One blood draw,a wider cancer net.

Catch the signalbefore the scan can.